Everything below concerns BPC-157. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-07-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Viral inactivation is the process of rendering a virus incapable of causing infection. It plays a critical role across multiple fields, including clinical medicine, diagnostics, research, and the food industry. In clinical practice, inactivation is essential for preventing viral transmission through blood products—such as transfusions and other biological materials—as well as in biopharmaceutical manufacturing. In diagnostic and research contexts, inactivation enables the safe study and manipulation of viruses without risking transmission to laboratory staff or healthcare personnel. Moreover, in vaccine development, inactivated viruses are employed to stimulate the host immune system, promoting the production of neutralizing antibodies. A wide range of viral inactivation techniques exist, ranging from physical removal by filtration to mechanical and chemical methods. The choice of technique depends on the specific context and intended purpose. In many situations, a combination of methods is employed—particularly when handling highly pathogenic viruses—where absolute sterility is crucial. Some of the more common viruses removed by these methods are the HIV-1 and HIV-2 viruses; hepatitis A, B, and C; and parvoviruses.
Ixazomib (trade name Ninlaro) is a drug for the treatment of multiple myeloma, a type of white blood cell cancer, in combination with other drugs. It is taken by mouth in the form of capsules. Common side effects include diarrhea, constipation and low platelet count. Like the older bortezomib (which can only be given by injection), it acts as a proteasome inhibitor, has orphan drug status in the US and Europe, and is a boronic acid derivative. The drug was developed by Takeda. In the US, it is approved since November 2015, and in the EU since November 2016.
Bismuth (83Bi) has 41 known isotopes, ranging from 184Bi to 224Bi. Bismuth has one nearly stable isotope but no stable isotopes, the standard atomic weight can be given from that isotope, bismuth-209. Though it is now known to be radioactive, it may still be considered practically stable because it has a half-life of 2.01×1019 years, which is more than a billion times the age of the universe. As a result, it is the longest lived known alpha emitter. Bismuth-209 is also the heaviest nearly stable isotope, with the longest lived isotope with a greater atomic weight being thorium-232. Besides 209Bi, the most stable bismuth radioisotopes are 210mBi with a half-life of 3.04 million years, 208Bi with a half-life of 368,000 years and 207Bi, with a half-life of 31.22 years, none of which occur in nature. All other isotopes have half-lives under 15 days, most under two hours. Of naturally occurring radioisotopes, the most stable is radiogenic 210Bi with a half-life of 5.012 days. 210mBi is unusual for being a nuclear isomer with a half-life many orders of magnitude longer than that of the ground state.
== Function == Through the diverse outputs of the orexin system, the orexin neurons in the lateral hypothalamus mediate an array of functions. Two of the most commonly noted functions of orexin peptides in the lateral hypothalamus are the promotion of feeding behavior and arousal (i.e., wakefulness). More generally, the orexinergic neural projections of the lateral hypothalamus are involved in thermoregulation, regulating gastrointestinal motility and gastrointestinal function by way of the dorsal nucleus of the vagus nerve, reducing pain and nociception through several output structures (e.g., periaqueductal gray matter), modulating the rewarding property of stimuli through the ventral tegmental area projections and other outputs in the reward system, regulating energy homeostasis and neuroendocrine functions (e.g., HPA axis, HPG axis, and HPT axis) through other hypothalamic outputs, and regulating visceral functions (e.g., respiration, blood pressure, and urination) via a group of structures in the brain stem, among other functions. The endocannabinoid system and the orexin system mediate many of the same cognitive and physical effects, and a significant overlap in their function and localization has been noted in a 2013 medical review; the CB1–OX1 receptor heterodimer produces a 100-fold amplification of the potency of the orexin receptor 1-mediated ERK pathway signaling. Unique functional interactions have been noted as well, such as an OX1-induced CB1 pressor response in the rostral ventrolateral medulla.
=== Administrative history === The ancient parish of Holyhead covered the majority of Holy Island. In 1832 a parliamentary borough was established covering just the area around the town itself, as a contributory borough to the Beaumaris Boroughs constituency. In 1860 a local government district was created covering the same area as the parliamentary borough, governed by an elected local board. Such local government districts were reconstituted as urban districts under the Local Government Act 1894. As part of the 1894 reforms, parishes were no long allowed to straddle district boundaries, and so the part of Holyhead parish outside the urban district became a separate parish called 'Holyhead Rural'. Holyhead Town Hall was completed in 1875 and served as both a public events venue and meeting place for the local board and the urban district council which replaced it. Holyhead Urban District was abolished in 1974, with its area instead becoming a community. District-level functions passed to Ynys Môn-Isle of Anglesey Borough Council, which in 1996 was reconstituted as a county council. The Holyhead Rural parish also became a community in 1974, and was renamed Trearddur in 1984.
Sources: en.wikipedia.org
Research suggests that graphene filters could outperform other techniques of desalination by a significant margin. In 2021, researchers found that a reusable graphene foam could efficiently filter uranium (and possibly other heavy metals such as lead, mercury and cadmium) from water at the rate of 4 grams of uranium/gram of graphene.
=== Activation by protease and metalloprotease === Plasmin and a member of matrix metalloproteinases (MMP) play a key role in promoting tumor invasion and tissue remodeling by inducing proteolysis of several ECM components. The TGF-β activation process involves the release of the LLC from the matrix, followed by further proteolysis of the LAP to release TGF-β to its receptors. MMP-9 and MMP-2 are known to cleave latent TGF-β. The LAP complex contains a protease-sensitive hinge region which can be the potential target for this liberation of TGF-β. Despite the fact that MMPs have been proven to play a key role in activating TGF-β, mice with mutations in MMP-9 and MMP-2 genes can still activate TGF-β and do not show any TGF-β deficiency phenotypes, this may reflect redundancy among the activating enzymes suggesting that other unknown proteases might be involved.
== Imaging == Via positron emission tomography imaging technique, NET has been selectively investigated. 11C ME@HAPTHI and 18F-MeNER are two NET selective radio tracers for PET imaging. Fluorescent substrates for the transporter can also be used to monitor the transporter rate in isolated organs or tissues, although these are not suitable for clinical imaging.
==== Alcohol ==== In contrast to other drugs consumed, alcohol is deposited directly in the hair. For this reason the investigation procedure looks for direct products of ethanol metabolism. The main part of alcohol is oxidized in the human body. This means it is released as water and carbon dioxide. One part of the alcohol reacts with fatty acids to produce esters. The sum of the concentrations of four of these fatty acid ethyl esters (FAEEs: ethyl myristate, ethyl palmitate, ethyl oleate and ethyl stearate) are used as indicators of the alcohol consumption. The amounts found in hair are measured in nanograms (one nanogram equals only one billionth of a gram), however with the benefit of modern technology, it is possible to detect such small amounts. In the detection of ethyl glucuronide, or EtG, testing can detect amounts in picograms (one picogram equals 0.001 nanograms). However, there is one major difference between most drugs and alcohol metabolites in the way in which they enter into the hair: on the one hand like other drugs FAEEs enter into the hair via the keratinocytes, the cells responsible for hair growth. These cells form the hair in the root and then grow through the skin surface taking any substances with them. On the other hand, the sebaceous glands produce FAEEs in the scalp and these migrate together with the sebum along the hair shaft (Auwärter et al., 2001, Pragst et al., 2004).
The Bard Gorlen series "Catamounts" (September 1996, The Magazine of Fantasy and Science Fiction) "Childrun" (August 2008, The Magazine of Fantasy and Science Fiction) "Quickstone" (March 2009, The Magazine of Fantasy and Science Fiction) "Bemused" (September/October 2013, The Magazine of Fantasy and Science Fiction) "Rooksnight" (May/June 2014, The Magazine of Fantasy and Science Fiction) "Catamounts" (Reprint) (August 2013, Lightspeed) "Belweather" (September 2013, Lightspeed) "Stillborne" (November/December 2017, The Magazine of Fantasy and Science Fiction) "Weeper" (September/October 2020, The Magazine of Fantasy and Science Fiction) "Underneath the Oversea" (November 2020)
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
The dry powder is the stable form and the dissolved form is comparatively fragile. Freezing a solution slows degradation but does not stop it, and repeated freezing and thawing adds further stress. Many laboratories therefore prepare small single-use portions rather than storing one large volume.